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Biomed AllianceAlliance for biomedical research in Europe» . . .we will focus on
general issues common to all
European scientists and
scientific organisations. «Europe is facing one of the most challen-
ging times in its history, with austerity
measures being applied across member
states that are leaving research pro-
grammes in uncertain territory. Funding
for European research and development
(R&D) programmes remains stagnant at
1.8% of European Union GDP, well short
of the 3.0% that was committed to in the
Lisbon summit of 2002. This stagnation
occurs while all of Europe’s major
competitors – namely the USA (2.7%),
Japan (3.4%) and most recently China –
continue to invest in their biomedical
research programmes. UNESCO data
from 2007 shows that China’s total
R&D investment was one third of that
of the entire EU. But continued invest-
ment and rising GDP means that China’s
investment is likely to quadruple by
2020, meaning its total R&D spending
will overtake Europe in a few years.
European biomedical research could be
left behind unless major steps are taken
to address this gulf in funding.
Yet it is not only how much money we
receive, but how we spend that money,
that has inspired the creation of the
Alliance for Biomedical Research in
Europe (Biomed Alliance) (see Box 1
for formation of the Alliance). For too
long the voices of researchers in Europe
have not had sufficient impact on pro-
posed research programmes by the
European Union. Such contact has, until
now, been sporadic and not produced theBOX 1: Formation of the alliance
The Biomed Alliance officially formed at
ameeting in Brussels in December 2010,
consisting of the four founding societies:
the European Association for the Study
of Diabetes (EASD), the European Society
for Cardiology (ESC), the European
Respiratory Society (ERS) and the
European Cancer Organisation (ECCO).
This first meeting in Brussels was
attended by 28 high-level executives
www.embomolmed.orgdesired results on research topics and
priorities. Our new Alliance aims to give a
single, powerful voice to the European
biomedical research community, that aims
to increase funding and ensure the correct
research priorities are given funding
across all biomedical disciplines.This does not mean that the Alliance
can speak on behalf of its members on
their specific research-related issues.
Instead, we will focus on general issues
common to all European scientists and
scientific organisations. These include
funding (both total and relative) of
European biomedical research, the need
for simplification of current EU procedures
– both for application and reporting – and
also the need to involve researchers in the
conception, development and evaluation
of innovative research. Here, the Alliance
can both convey proposals from its
members and help identify suitable
reviewers of applications. This latter part
is important since there is essentially no
way to appeal decisions made by the
reviewers of applications. The so-called
redress procedure currently used has led to
hardly any changes in decisions.from European biomedical societies,
representing some 400,000 researchers
across the continent. Nine of these
societies have formally joined the
Alliance: the European Association for
the Study of the Liver (EASL), the European
College of Neuropsychopharmacology
(ECNP), the European Hematology Asso-
ciation (EHA), the European Society of
Human Reproduction and Embryology
EMBO Mol Med 3, 505–506Another major problem that the Alli-
ance will highlight is the lack of continuity
of EU-funded research. The programs
terminate after 3–5 years irrespective of
whether or not unique results and infra-
structures have been developed. There is
no instrument in place for the European
Commission (EC) to recommend a con-
tinuation, and experienced and successful
collaborations that have achieving mean-
ingful results are discontinued. This is a
waste of taxpayers’ money as well as
resources and an inefficient use of inno-
vative research. The new alliance will
encourage the EC to create extension
conditions that will allow work to con-
tinue where appropriate.
These are just some of the major issues
that the Alliance has defined as major
objectives in order to promote European
biomedical research and to boost scientific
excellence and knowledge as drivers of
future growth (see Box 2 for a summary of
aims). In fact, the Alliance and its members
submitted a joint response to the EC Green
paper consultation ‘From Challenges to
Opportunities: Towards a Common Stra-
tegic Framework for EU Research and
Innovation Funding’. (The link to the
Green paper can be found on Alliance
homepage: www.biomedeurope.org).
The Biomed Alliance has been wel-
comed by the European Union. Our first
meeting was attended by Dr Ruxandra
Draghia-Akli, Director of the Health
Directorate and the Directorate-General(ESHRE), the European Association of
Nuclear Medicine (EANM), the Federa-
tion of European Biochemical Societies
(FEBS), the European Society of Radi-
ology (ESR), the European Society of
Hypertension (ESH) and the European
Federation of Immunological Societies
(EFIS). Other societies are in the process
of joining.
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BOX 2: Aims of the alliance
 To set up a structured communica-
tion between the Alliance and the
European Commission, the Eur-
opean Parliament (EP) and Council
of Ministers.
 To establish more support for bio-
medical research within the EP and
EC, including lobbying for more
funding.
 To simplify the bureaucracy around
applying for European funding that
many researchers currently find overly
complex.
 To provide access to European
funding to allow successful colla-
borations that have delivered
results to continue their work.
 To facilitate researcher mobility
across Europe.
Ulf Smith
506for Research and Innovation in the
European Commission (EC). She has
pointed out that the new alliance has a
fantastic opportunity to influence research
programmes and lobby for extra funding,
both from the EC itself and individual
member states. She also foresees regular
consultation with the alliance forming
part of the formal procedures for the next
funding cycle (Framework Programme 8)
covering the period 2014–2020.Karin Sipido
Caroline Dive
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» The remit of the Biomed
Alliance will extend beyond
the issues of funding and
research priorities. «The remit of the Biomed Alliance will
extend beyond the issues of funding and
research priorities. There are other issues
that are best addressed together as one
voice. Researcher mobility across Europe
is an issue that affects all of us, no matter
what our discipline. Researchers are
currently reluctant to relocate between
EU member states after they reach an age
of 40 years, due to concerns about loss of
pension entitlements. And we need to
better communicate the importance of
biomedical research to the general public
in order to raise its profile and facilitate
our drive for more funding.
Ultimately, Europe’s biomedical
research can only remain competitive if
the member states meet their R&D spend-
ing commitments that they made in Lisbon
9 years ago. As far as EC funding is
concerned, only 10% of the funds for
2008–2013 have been allocated for health. 2011 EMBO Molecular Medicine EMBO Mol Med 3, 505–506We believe this should be raised to 30%,
since only at that level can we compete on
a level with the US National Institutes of
Health, that spend some US$30 billion per
year on their research programmes. We
must make policymakers understand the
direct connection between a strong and
competitive research sector and a healthy
and active population. The actions to be
taken by the Alliance will also help address
such issues as Europe’s ballooning chronic
disease burden (chronic diseases account
for 86% of the WHO European region’s
mortality). New innovations are needed to
prevent and treat disease, and these aims
cannot be accomplished without adequate
backing from both member states and the
EU. The Biomed Alliance will ensure that
researchers are no longer on the fringe of
policymaking, but at the heart of it.
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